%2019-Nov-2008_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
19.11.2008 |
IDENTIFICATION DETAILS
|
Name : |
UNIVERSAL INDUSTRIAL PHARMACEUTICAL CO (UNI PHARMA) |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2007 |
|
|
|
|
Year of Establishment : |
1999 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and export of pharmaceutical and veterinary preparations |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 750,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : UNIVERSAL INDUSTRIAL PHARMACEUTICAL CO (UNI PHARMA)
Country of Origin :
Legal Form : Egyptian Joint Stock Company
Registration Date : 1999
Issued Capital : £E 14,000,000
Paid up Capital : £E 14,000,000
Total Workforce : 400
Activities : Manufacture and export of pharmaceutical and veterinary preparations
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 750,000
COMPANY NAME
UNIVERSAL
INDUSTRIAL PHARMACEUTICAL CO (UNI PHARMA)
ADDRESS
Registered &
Physical Address
Street :
Area :
Town :
Country :
Telephone : (20-2) 22748492
Facsimile : (20-2) 22748636
Premises
Subject operates
from a large suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office
(s)
Location Description
·
1st Industrial Zone, Plot 13, Block 13013 Owned factory premises
El Obour City
Tel: (20-2) 26103233
/ 26103234 / 26103236
Fax: (20-2) 26103235
·
Ceramica Cleopatra Building, 7th Floor Rented sales office
Tel: (20-2)
22737107
Fax: (20-2)
22737107
KEY PRINCIPALS
Name Position
·
Dr. El Sayed El Sayed El Ganayni Chairman
·
Reda El Dessouki Finance
Manager
·
Ayman Shehata Export
Manager
·
Nassef Ahmed Ali Factory
Manager
·
Ayat Ismail Office
Manager
LEGAL FORM & OWNERS
Date of Establishment : 1999
Legal Form :
Egyptian Joint Stock
Company
Issued Capital : £E 20,000,000
Issued Capital : £E 14,000,000
Paid up Capital : £E 14,000,000
Name of Shareholder (s) Percentage
·
Dr. El Sayed El Sayed El Ganayni 15%
·
Fayza Mohamed Bekhati 20%
·
Mahmoud El Sayed El Ganayni 25%
·
Mohamed El Sayed El Sayed El Ganayni 20%
·
Serylan El Sayed El Sayed El Ganayni 10%
·
Dalia El Sayed El Sayed El Ganayni 10%
OPERATIONS
Activities: Engaged in the
manufacture and export of pharmaceutical and veterinary preparations including
anaesthetics, sedatives and
spasmolytics, disinfectants and antiseptic products, electuaries, fish oils,
iron dextran, and diagnostic kits
Import
Countries:
Export
Countries:
Brand Names: UNI PHARMA
Operating Trend: Steady
Subject has a
workforce of approximately 400 employees.
FINANCIAL DATA
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/06: Year
Ending 31/12/07:
Total Sales £E 37,800,000 £E 40,000,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
BANKERS
·
National
Bank of
24,
Tel: (20-2) 33924175
Fax: (20-2) 33924143
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
Date of
transaction October
2005
Credit amount 100,000
Amount overdue 0
Payment terms 60
days
Payment Method Letters
of Credit
Paying record No
Complaints
Currency
GENERAL COMMENTS
During the course
of this investigation nothing detrimental was uncovered regarding subject’s operating
history or the manner in which payments are fulfilled. As such the company is
considered to be a fair trade risk and the above credit figure is within
subject’s financial means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.74 |
|
|
1 |
Rs.74.37 |
|
Euro |
1 |
Rs.62.78 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)